MedTrace Logo

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

NCT05863845 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-05-18

No results posted yet for this study

Summary

This single-center, randomized clinical study will evaluate the efficacy and safety of Venetoclax combined with BEAM Pretreatment Regimen in ASCT treatment of DLBCL patients.

Conditions

Interventions

DRUG

Venetoclax

100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO

DRUG

Carmustine

300mg/m2 day -7, Given IV

DRUG

Cytarabine

100mg/m2/d, day -6 to day -3, Given IV

DRUG

Etoposide

200mg/m2/d, day -6 to day -3, Given IV

DRUG

Melphalan

140mg/m2, day -2, Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo hematopoietic cell transplantation

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-11-30
Completion
2025-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05863845 on ClinicalTrials.gov